When Clinical Evidence Begins to Influence Enterprise Value
Clinical evidence is a capital allocation decision. Clinical evidence is not downstream. It determines approval durability, post‑market burden, lifecycle cost, and valuation trajectory.
SHOTUNE provides founder-led clinical governance for Class I–III medical devices where evidence must withstand FDA, EU MDR, audit, and diligence scrutiny.
What This Protects
- Approval durability and claims defensibility
- Controlled PMCF and post-market exposure
- Lifecycle optionality across markets
- Diligence confidence
- Funding and valuation stability
Over-studying destroys capital. Under-studying destroys approvals.Governance prevents both.
Escalate Clinical Strategy When:
- Regulators challenge or reinterpret your evidence
- PMCF expectations expand beyond projections
- Existing data fails to clearly support claims
- Studies are misaligned with commercialization timelines
- Clinical uncertainty begins affecting funding or valuation
- Internal teams lack senior clinical–regulatory judgment
Escalation restores coherence before risk becomes exposure.
Escalate Quality Governance When:
| Alternative | What They Provide | Limitation | What You Actually Need |
|---|---|---|---|
| CROs | Study execution | Execution without strategic ownership | Evidence architecture + executive judgment |
| Academic Advisors | Scientific rigor | Scientific rigor without regulatory realism | Regulator-aligned, commercially grounded strategy |
| Internal Teams | Bandwidth | Limited bandwidth under escalation | Embedded fractional senior clinical leadership |
Clinical strategy is enterprise governance—not study management.
Strategic Scope
CER/CEP strategy
PMCF and PMS governance
Clinical investigation proportionality decisions
Evidence gap assessment and remediation
Integration of clinical, regulatory, and claims strategy
Execution follows strategy—not the reverse.
How We Work
SHOTUNE governs evidence as an enterprise asset, not a set of disconnected studies
Owns: clinical strategy, evidence architecture, tradeoff logic (speed vs durability), regulator‑facing narratives.
You own: budget and board decisions.
Cadence: weekly working sessions, monthly executive checkpoints, escalation as required.
Providing Clarity in Every Step of Your Clinical Journey
Founder Accountability
- All clinical engagements are personally led by Dr. Shola Sulaimon, former global regulatory and clinical leader at Medtronic, with 18+ years of experience and 70+ CE Mark approvals across high-risk portfolios.
- If clinical uncertainty is influencing executive risk conversations, escalation requires senior judgment.